The board of directors of biopharmaceutical company Merck (NYSE:MRK) declared a dividend of USD0.55 per share of the company's common stock for the the third quarter of 2019.
This dividend is payable on 8 July 2019 to shareholders of record at the close of business as of 17 June 2019.
Through the company's prescription medicines, vaccines, biologic therapies and animal health products, it operate in 140 countries to deliver innovative health solutions.
According to the company, it continues to be at the forefront of research to advance the prevention and treatment of diseases including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer's disease and infectious diseases including HIV and Ebola.
Kromek collaborates on next-gen CT detector technology
Gilead Sciences initiates Phase 2 trial in Europe to evaluate lenacapavir for HIV prevention
European Commission grants authorisation to ViiV Healthcare's Apretude for prevention of HIV
Celanese to supply VitalDose drug delivery platform for Population Council's MPT Intravaginal Ring
Henry Schein introduces equipment repair subscription - Henry Schein Thrive Service Plus
Seres Therapeutics provides business updates and reports Q2 2023 financial results